RxDoctor Payments Data

Joshua Levar

Ophthalmology · New Braunfels, TXNPI 1164652509

Payments from drug & device makers

$2,478in general payments, 2019–2025

Across 131 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$800
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$492
  • Bausch & Lomb Americas Inc.$240
  • Biotissue Holdings Inc.$151
  • Mallinckrodt Hospital Products Inc.$151
  • Sun Pharmaceutical Industries Inc.$114
  • plus $529 from 12 others

What the payments were for

  • Food & beverage$2,478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,478 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$270,150
Medicare patients
1,062
Services billed
2,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lotemax SmLoteprednol Etabonate65$15,815
Cyclosporine13$9,060
ProlensaBromfenac Sodium18$6,093
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$3,213
VyzultaLatanoprostene Bunod13$2,960
Prednisolone Acetate93$2,788
MoxifloxacinMoxifloxacin Hcl101$2,298
Latanoprost178$1,581
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat90$1,237
Fluorometholone15$1,062
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha54$608
Timolol Maleate81$601
Brimonidine Tartrate30$540
ErythromycinErythromycin Base20$172
Acyclovir23$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa$492$21,90883 claims
Bausch & Lomb Americas Inc.Vyzulta$240$2,96013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →